More Evidence Schizophrenia Combo Therapy Blunts Weight Gain More Evidence Schizophrenia Combo Therapy Blunts Weight Gain

The combination of olanzapine and samidorphan, shown to mitigate the weight gain observed with olanzapine alone in ENLIGHTEN-2, continues to prevent weight gain, new results from an extension study show.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

Related Links:

Publication date: Available online 14 April 2019Source: The Journal of Steroid Biochemistry and Molecular BiologyAuthor(s): Jan-Ake Gustafsson, Anders Strom, Margaret WarnerAbstractERbeta (ERβ) celebrated its 20th birthday in 2016 and although the overwhelming data in the literature indicate a role for this receptor in the control of epithelial proliferation, neurodegeneration and immune function, no ERβ agonists have yet made it to the clinics. This is the situation, despite the fact that very good safe ERβ agonists have been synthesized and at least one has been donated to the NIH for distribution to resea...
Source: The Journal of Steroid Biochemistry and Molecular Biology - Category: Biochemistry Source Type: research
Roseline Yong* and Kyoko NomuraPublic Health Department, The Graduate School of Medicine, Akita University, Akita, JapanThere have been few population studies of hikikomori (that is, prolonged social withdrawal and isolation), and the basic correlating factors of hikikomori are yet to be identified. Therefore, this study aimed to identify the associated basic characteristics and psychiatric factors of hikikomori. Data were obtained from the Survey of Young People’s Attitudes of 5,000 residents (aged 15–39 years) who were randomly selected from 200 urban and suburban municipalities in Japan in February 2010. The...
Source: Frontiers in Psychiatry - Category: Psychiatry Source Type: research
In conclusion, our data show some of the brain modifications probably responsible for the behavioral phenotype associated with TBI and suggest the CBD as a pharmacological tool to improve neurological dysfunctions caused by the trauma. Introduction The phytocannabinoid cannabidiol (CBD), the major non-psychoactive constituent of Cannabis sativa, exhibits a broad spectrum of potential therapeutic properties, including neuroprotective effects in Central Nervous System (CNS) disorders (Fernández-Ruiz et al., 2013; De Gregorio et al., 2018; Schonhofen et al., 2018). Through a multitarget mechanism, CBD shows pot...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Conclusion and Future Perspectives Although interesting data have come from pharmacogenetics, neuroimaging and the interaction of both fields of study, few converging findings are available that describe the antipsychotic treatment response and resistance mechanisms in schizophrenia (DeLisi and Fleischhacker, 2016). Based on the available evidence, the results from both neuroimaging and pharmacogenetic/pharmacogenomic studies point to an overlap in the neurobiological vulnerability risk factors influencing the antipsychotic drug response in schizophrenia and the risk factors underlying schizophrenia itself. Currently for ...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Conclusion: Based on current evidence, limited inferences can be made regarding the efficacy of probiotics in schizophrenia. Although probiotics may have other benefits, for example to regulate bowel movement and ameliorate the metabolic effects of antipsychotic medications, the clinical utility of probiotics in the treatment of schizophrenia patients remains to be validated by future clinical studies.Neuropsychobiology
Source: Neuropsychobiology - Category: Psychiatry & Psychology Source Type: research
A smoking cessation intervention tailored to people with severe mental illness (SMI) such as schizophrenia can lead to reduced smoking and improved physical health in the short term, reports astudy published inLancet Psychiatry.Compared with patients with SMI who received standard smoking cessation treatment, patients who received the tailored intervention that combined behavioral and pharmacological therapy were more than twice as likely to have successfully quit smoking at six months. These improvements, however, were maintained by only 15% of the patients at the 12-month mark.“The results of the SCIMITAR+ [Smoking...
Source: Psychiatr News - Category: Psychiatry Tags: bipolar disorder cigarettes Lancet Psychiatry schizophrenia serious mental illness Simon Gilbody SMI smoking cessation Source Type: research
A gluten-free diet may reduce symptoms in a particular subset of patients with schizophrenia, early research suggests.Medscape Medical News
Source: Medscape Psychiatry Headlines - Category: Psychiatry Tags: Psychiatry News Source Type: news
Authors: Köhler-Forsberg O, Sørensen HJ, Benros ME, Petersen L, Gasse C Abstract BACKGROUND: Somatic diseases have been associated with an increased risk for subsequent schizophrenia; however, it is unknown whether prior somatic diseases negatively affect early treatment outcomes after a first-time schizophrenia diagnosis. METHODS: We included all individuals born in Denmark after January 1st, 1977 and first-time diagnosed with schizophrenia between January 1st, 1996 and December 31st, 2015. We identified all life-time somatic hospital contacts and all prescriptions within the year before the first-...
Source: Journal of the Association of European Psychiatrists - Category: Psychiatry Tags: Eur Psychiatry Source Type: research
Schizophrenia (SCZ) is a heritable, refractory, and devastating psychiatric disorder. Previous studies have shown that the variants of CUB and sushi multiple domains 1 (CSMD1) demonstrate significant genome-wide ...
Source: BMC Psychiatry - Category: Psychiatry Authors: Tags: Research article Source Type: research
Conclusion: Our study is one of the few studies focused on drug-naive or minimally treated patients at pre- or early-psychotic states. Our results exhibited impaired performance in sensory gating and deviance detection shown by certain parameters. A longitudinal study with larger sample sizes will be helpful to provide more evidence to elucidate the role of antipsychotics on an individual’s neurophysiological performance at different stages of psychosis.IntroductionNeuroscience tools have been widely employed in schizophrenia research in recent decades (1–3). Neurobiological impairments precede the onset of a f...
Source: Frontiers in Psychiatry - Category: Psychiatry Source Type: research
More News: Health | Primary Care | Schizophrenia | Study | Zyprexa